Avexima

OJSC Aveksima is a full-cycle pharmaceutical company operating in three main areas: the development, production and promotion of drugs.

History

2023

Ivan Halepo's appointment as CEO

On October 2, 2023, the Russian pharmaceutical company Aveksima announced the change of CEO. He was appointed Ivan Halepo, who previously worked in the company as deputy head of sales and marketing. Read more here.

Start of construction of a pharmaceutical plant in Solnechnogorsk

The pharmaceutical company Aveksima has begun construction of a plant in Solnechnogorsk near Moscow. This was announced on June 26, 2023 by the Ministry of Investment, Industry and Science of the Moscow Region.

At the new enterprise in the Moscow region, Aveksima will place laboratories and pilot industrial sites for the development of new drugs for the treatment of diseases in the field of cardiology, gastroenterology, gynecology, dermatology, neurology, immunology and oncology. The area of ​ ​ the object will exceed 170 thousand square meters. m, it is planned to create more than 1,500 jobs there. The company plans to complete the construction of the first stage in 2027. The entire project with investments of 6.5 billion rubles will be implemented within 8 years, said at the end of June 2023, Deputy Prime Minister - Minister of Investment, Industry and Science of the Moscow Region Ekaterina Zinovieva.

Pharmaceutical plant project in Solnechnogorsk

It is noted that the company's production complex will be built in accordance with the requirements of international quality standards. All medicinal products will be produced in "clean rooms" and undergo strict control using the most modern laboratory equipment at all stages of production - from raw materials and ingredients to packaging and labeling of containers.

At the enterprise in the industrial park "Esipovo" more than 20 production sites will be built, equipped with high-tech production lines using advanced engineering solutions. Also, three industries will be organized at the plant: for the production of biotechnological drugs, cytostatics and beta-lactam antibiotics. And, importantly, many of these drugs will be import substitutes, "said Vladimir Slipenkin, General Director of the Moscow Region Development Corporation.[1]

2022: Additional agreement with the Moscow Region Development Corporation for the production of Nobazit

On January 18, 2022, the Moscow Region Development Corporation announced that the pharmaceutical company Aveksima is organizing the production of the antiviral drug Nobazit to combat COVID-19 as part of an investment project in the Yesipovo enterprise near Moscow.

An additional agreement between Aveksima and the Moscow Region Development Corporation on expanding cooperation within the framework of the investment project was signed in December 2021. Read more here.